ESPE Abstracts (2024) 98 P2-260

1Pediatric Endocrinology Unit, Marques of Valdecilla University Hospital, Santander, Spain. 2IDIVAL, Santander, Spain. 3Endocrinology Unit, Marques of Valdecilla University Hospital, Santander, Spain. 4Psychosexologist, Marqués of Valdecilla University Hospital, Santander, Spain


Background: In recent years, the number of consultations of transgender children and adolescents has gradually increased. In our region, this group receives care from a specialized multidisciplinary team, formed in 2015. It is basically composed of a psychosexologist, two adult endocrinologist, a pediatric endocrinologist, among other specialists.

Objective: To describe the characteristics of the children and adolescents referred to the pediatric endocrinology unit, within the care program for transgender people.

Material and Methods: retrospective study of all people under 16 years of age, assisted in the pediatric endocrinology unit within the protocol for care of transgender people, in the last 9 years (January 1, 2015 to December 31, 2023), in a region of northern Spain.

Results: During this period, 50 children and adolescents received assessment in our pediatric endocrinology unit. The annual average was 6.2±3.8 people per year (range 3-12), with significant increase in the last 3 years. 70% (35) assigned female at birth (AFAB). Average age at first consultation 13.1±2.7 year (range 5.3-16.2): 13.5±2.2 (range 6.5-15.8) in AFAB and 12.4±3.5 years (range 5.3-16.2) in assigned male at birth (AMAB). Puberty stage: 18% (9) prepubertal, 20% (10) Tanner II-III, 62% (31) Tanner IV-V. 76% had already made social transition. Comorbility in 30% (15): 16% (8) mental health concerns, 12% (6) obesity. Current age: 16.3±3 years (8.9-22). Diagnosis: 6% (3) non-binary person, 10% (5) gender dysphoria, 24% (12) trans female person, 60% (30) trans male person. 68% (34) recibed puberty-blocking medication (GnRH analogues): 9 trans female: mean age 14.0±2.1 years (10.1-16.4), 3 Tanner II, 2 Tanner III; and 25 trans male: mean age 14.2±1.5 years (8.9-16), 2 Tanner II, 2 Tanner III. 34% (17) gender-affirming hormone therapy: 4 trans female: mean age 15.9 ±1.6 years (14.2-17.2); and 13 trans male: mean age 16.2±0.6 years (15.5-17.4). 80% (40) have made social transition and 40% (20) legal transition. 26% (13) without follow-up by our team: 2 cisgender identification, 3 due to transfer of region, 3 detransition and 5 for unknown reasons.

Conclusions: The number of consultations has clearly increased in the last 3 years. In our group of people under 16 years of age there is a clear predominance of AFAB, but the AMAB consult earlier. We must be cautious when starting treatments, especially non-reversible ones, since there is a high proportion of associated mental health concerns and a not inconsiderable percentage of follow-up abandonment.

Volume 98

62nd Annual ESPE (ESPE 2024)

Liverpool, UK
16 Nov 2024 - 18 Nov 2024

European Society for Paediatric Endocrinology 

Browse other volumes

Article tools

My recent searches